X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (6) 6
female (6) 6
humans (6) 6
index medicus (6) 6
male (6) 6
middle aged (6) 6
adult (5) 5
ipilimumab (5) 5
melanoma (5) 5
oncology (5) 5
treatment outcome (5) 5
cancer (4) 4
care and treatment (4) 4
melanoma - drug therapy (4) 4
skin neoplasms - drug therapy (4) 4
aged, 80 and over (3) 3
analysis (3) 3
disease-free survival (3) 3
drug therapy (3) 3
efficacy (3) 3
melanoma - mortality (3) 3
metastatic melanoma (3) 3
skin neoplasms - mortality (3) 3
survival rate (3) 3
anti-pd-1 (2) 2
dacarbazine (2) 2
diagnosis (2) 2
dosage and administration (2) 2
immune-related adverse events (2) 2
immunology (2) 2
immunotherapy (2) 2
ipilimumab - therapeutic use (2) 2
kaplan-meier estimate (2) 2
melanoma - secondary (2) 2
metastasis (2) 2
neoplasm staging (2) 2
overall survival (2) 2
pembrolizumab (2) 2
pharmacology & pharmacy (2) 2
safety (2) 2
safety and security measures (2) 2
survival (2) 2
therapy (2) 2
abridged index medicus (1) 1
activated killer-cells (1) 1
adjuvant treatment of cancer (1) 1
adjuvants, immunologic - adverse effects (1) 1
adjuvants, immunologic - therapeutic use (1) 1
adolescent (1) 1
advanced cutaneous melanoma (1) 1
adverse events (1) 1
anemia - chemically induced (1) 1
angiogenesis inhibitors (1) 1
anti-pd-1 therapy (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antibody (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, immunological - adverse effects (1) 1
antineoplastic agents, immunological - therapeutic use (1) 1
apoptosis (1) 1
b7-h1 antigen - analysis (1) 1
b7-h1 antigen - antagonists & inhibitors (1) 1
benefit (1) 1
biomarker (1) 1
biomarkers, tumor - analysis (1) 1
blotting, western (1) 1
cancer research (1) 1
cancer vaccines - therapeutic use (1) 1
carcinoma (1) 1
carcinoma, renal cell - drug therapy (1) 1
carcinoma, renal cell - secondary (1) 1
clinical practice (1) 1
clinical-practice guidelines (1) 1
colitis (1) 1
committees (1) 1
cutaneous melanoma (1) 1
cytotoxic lymphocytes (1) 1
death (1) 1
dendritic cells (1) 1
disease control (1) 1
disease progression (1) 1
double-blind method (1) 1
down-regulation (1) 1
drug costs (1) 1
drug use (1) 1
dyspnea - chemically induced (1) 1
economic burden (1) 1
eortc 18952 (1) 1
everolimus (1) 1
experience (1) 1
fatigue - chemically induced (1) 1
follow-up (1) 1
france (1) 1
genes, mhc class i - physiology (1) 1
granzyme b (1) 1
granzyme-b inhibitor (1) 1
granzymes (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Journal of Immunotherapy, ISSN 1524-9557, 07/2019, Volume 42, Issue 6, pp. 208 - 214
Toxicity of immune checkpoint inhibitors such as ipilimumab and nivolumab is likely associated with clinical efficacy. In this study, we aim to evaluate this... 
disease control | overall survival | pembrolizumab | melanoma | adverse events | progression-free survival | MEDICINE, RESEARCH & EXPERIMENTAL | EFFICACY | SAFETY | IMMUNOLOGY | IMMUNE | ONCOLOGY | ANTI-PD-1 | NIVOLUMAB | IPILIMUMAB | Treatment outcome | Drug therapy | Analysis | Melanoma
Journal Article
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 04/2018, Volume 29, Issue 6, pp. 579 - 588
Journal Article
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 07/2018, Volume 29, Issue 6, pp. 572 - 578
Journal Article
Cancer Immunology Immunotherapy, ISSN 0340-7004, 05/2014, Volume 63, Issue 5, pp. 449 - 458
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.